Planned Abscopal Effect with Concurrent Pembrolizumab and Ablative Radiotherapy to Pulmonary Metastasis: A Case Report and Review of the Literature by Yu-Ting Lee, Chien-Chin Chen, Hsiya Chao, Chih-Chia Chang, Cheng-Yen Lee

Subjects: Get full text

Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study” by Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim

Subjects: Get full text

Inflammation-targeted delivery of Urolithin A mitigates chemical- and immune checkpoint inhibitor-induced colitis by Sweta Ghosh, Rajbir Singh, Tanu Jain Goap, Omprakash Sunnapu, Zachary M. Vanwinkle, Hong Li, Syam P. Nukavarapu, Gerald W. Dryden, Bodduluri Haribabu, Praveen Kumar Vemula, Venkatakrishna Rao Jala

Subjects: Get full text

Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective lon... by Javier García-Corbacho, Alberto Indacochea, Iván Victoria, Débora Moreno, Laura Angelats, Azucena E. González Navarro, Laura Mezquita, Fara Brasó-Maristany, Patricia Galván, Begoña Mellado, Nuria Viñolas, Tamara Sauri, Miquel Nogué, Barbara Adamo, Joan Maurel, Estela Pineda, Lydia Gaba, Oscar Reig, Neus Basté, Esther Sanfeliu, Manel Juan, Aleix Prat, Francesco Schettini

Subjects: Get full text

Clinical outcomes of endocrine and other disorders induced by immune checkpoint inhibitors in Japanese patients by Yuichiro Iwamoto, Tomohiko Kimura, Kazunori Dan, Hideyuki Iwamoto, Junpei Sanada, Yoshiro Fushimi, Yukino Katakura, Masashi Shimoda, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto

Subjects: Get full text

Anti-Diabetic Therapies and Cancer: From Bench to Bedside by Dimitris Kounatidis, Natalia G. Vallianou, Irene Karampela, Eleni Rebelos, Marina Kouveletsou, Vasileios Dalopoulos, Petros Koufopoulos, Evanthia Diakoumopoulou, Nikolaos Tentolouris, Maria Dalamaga

Subjects: Get full text

First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study by Aida Piedra, Aida Piedra, Sergio Martínez-Recio, Ainhoa Hernández, Teresa Morán, Edurne Arriola, Jordi Recuero-Borau, Manuel Cobo, Patricia Cordeiro, Joaquín Mosquera, Manuel Fernández, Rosario García-Campelo, Antonio Calles, Rosa Álvarez, María Zapata-García, Dolores Isla, Ana Callejo, Patricia Iranzo, Jorgina Serra-López, Andrés Barba, Ivana Sullivan, Enriqueta Felip, Margarita Majem

Subjects: Get full text